GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

As you might know, GSK plc (LON:GSK) recently reported its interim numbers. GSK reported UK£16b in revenue, roughly in line ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

British drugmaker GSK Plc (GSK) on Wednesday announced that it now expects full-year earnings and turnover to be toward the ...

Shares of GSK PLC GSK slid 3.04% to £14.18 Thursday, on what proved to be an all-around rough trading session for the stock ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.

GSK is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Momentum investors should take note of this Medical stock.

GSK is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.23; value investors should ...